Annals of Clinical and Translational Neurology is a premier journal published by WILEY, focusing on the fields of neurology and neuroscience. Since its inception in 2014, it has established itself as an Open Access platform, providing unrestricted access to cutting-edge research to promote scientific collaboration and innovation. With an impressive Impact Factor residing in the top quartile (Q1) for both clinical neurology and miscellaneous neuroscience in 2023, this journal ranks #52 out of 400 in the Neurology category and #22 out of 113 in General Neuroscience, indicating its significant contribution to the field. The journal welcomes submissions that address emerging trends and challenges in translational neurology, aiming to bridge the gap between laboratory research and clinical practice. By disseminating high-quality research and fostering a community of scholars, Annals of Clinical and Translational Neurology plays a vital role in advancing our understanding of neurological disorders and improving patient care worldwide.

Multiple Sclerosis and Related Disorders, published by Elsevier Science Ltd, is a leading journal that serves as a vital resource in the field of neurology, particularly focused on multiple sclerosis and its associated conditions. This esteemed journal, which holds a Q1 ranking in Medicine (miscellaneous) and Q2 ranking in both Neurology and Clinical Neurology, delivers high-impact research findings and clinical insights crucial for advancing the understanding and management of multiple sclerosis. With an ISSN of 2211-0348 and an E-ISSN of 2211-0356, it provides valuable content from 2012 to 2024 aimed at researchers, healthcare professionals, and students dedicated to improving patient outcomes and fostering innovative strategies in treatment. Additionally, the journal's presence in the Scopus rankings highlights its relevance and influence in the academic community, ranking 121 out of 400 in Clinical Neurology and 59 out of 192 in Neuroscience. This comprehensive platform encourages the dissemination of cutting-edge knowledge and clinical practices, making it an essential tool for those committed to the field of neurology and related research.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

NEUROSCIENTIST is a leading journal in the field of clinical neurology and neuroscience, published by SAGE Publications Inc. With an impressive impact factor reflected in its Q1 quartile ranking in both clinical neurology and miscellaneous neuroscience as of 2023, this journal positions itself as a crucial platform for the latest research and advancements in the neural sciences. Spanning from 1995 to 2024, NEUROSCIENTIST features a range of high-quality, peer-reviewed articles that cater to researchers, practitioners, and students alike. Although it does not offer Open Access options, the journal remains a vital resource owing to its Scopus rankings, situating it within the top percentile of its categories: ranked #28 out of 400 in clinical neurology and #15 out of 113 in general neuroscience. The journal's commitment to disseminating significant findings underlines its importance in fostering advancements in neurological understanding and treatment.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

ANNALS OF NEUROLOGY, published by Wiley, stands as a leading journal in the field of neurology, renowned for its rigorous peer-reviewed articles that contribute significantly to the understanding of neurological disorders and advances in clinical practices. With an impressive impact factor and ranked Q1 in both neurology and clinical neurology categories, this journal positions itself among the top repositories of cutting-edge research, indexed in Scopus with exemplary ranks in the 98th and 97th percentiles respectively. Since its inception in 1977 and with a commitment to excellence extending to 2024 and beyond, ANNALS OF NEUROLOGY aims to disseminate groundbreaking studies and foster dialogue within the academic community, making it an essential resource for researchers, healthcare professionals, and students dedicated to neurology. Although it does not currently offer open access, its accessibility through institutional subscriptions facilitates widespread scholarly engagement.

BMC NEUROSCIENCE is a prominent open access journal dedicated to the dissemination of high-quality research within the dynamic and rapidly evolving field of neuroscience. Published by BMC, a well-respected leader in open access publishing, this journal facilitates the free exchange of knowledge since its inception in 2000. With the ISSN 1471-2202, BMC NEUROSCIENCE aims to address the diverse interests of the neuroscience community by covering a broad spectrum of topics, ranging from cellular and molecular neuroscience to general neurological studies, thus appealing to researchers, professionals, and students alike. Although it currently holds a Q4 ranking in Cellular and Molecular Neuroscience and a Q3 rank in miscellaneous Neuroscience categories, its commitment to advancing the understanding of brain function and disorders remains steadfast. The journal features a user-friendly Open Access model, ensuring that critical research findings are readily accessible to everyone, fostering collaboration and innovation in the field. As the journal continues to evolve towards its convergence years of 2024, it aspires to enhance its impact and global reach, making it a valuable resource for anyone interested in advancing neuroscience research.